EmbryVu preimplantation genetic screening

A critical step in optimizing IVF outcomes

Order form

Preimplantation genetic screening (PGS) identifies embryos with the correct number of chromosomes to improve the chances of a successful pregnancy.

When an embryo has extra or missing chromosomes, that’s a condition known as aneuploidy. Most aneuploid embryos do not result in a healthy live birth: many lead to spontaneous miscarriage, some fail to implant in the uterus, and some result in a baby with birth defects, intellectual disability, and/or other health problems. Aneuploidy occurs across all age groups, but after a woman reaches age 35, the proportion of aneuploid embryos increases rapidly.

Why EmbryVu?

  • Delivers accurate, timely, and actionable results

  • Detects key chromosome abnormalities that other NGS technologies miss, including whole chromosome aneuploidy, segmental aneuploidy, triploidy, haploidy, and select uniparental isodisomy

  • Extensive validation of sensitivity and specificity

  • Patent protected, industry-leading innovation

  • CLIA-certified and CAP-accredited to perform high-complexity clinical genetic testing